Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Naoya Kitamura, Shinya Sento, Yasumasa Yoshizawa, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 240-240
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 911
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 59
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
Che-Wei Wang, Pulak Kumar Biswas, Atikul Islam, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 413-413
Open Access | Times Cited: 13
The Prognostic Value and Immune Landscapes of a m6A/m5C/m1A-Related LncRNAs Signature in Head and Neck Squamous Cell Carcinoma
Enhao Wang, Yang Li, Ruijie Ming, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 50
The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas
Nobuo Kondoh, Masako Mizuno‐Kamiya
Cancers (2022) Vol. 14, Iss. 12, pp. 2884-2884
Open Access | Times Cited: 33
Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Chenhang Yu, Qiang Li, Yu Zhang, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 33
Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications.
Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, et al.
PubMed (2023) Vol. 22, pp. 146-168
Closed Access | Times Cited: 19
Curcumin and analogues against head and neck cancer: From drug delivery to molecular mechanisms
Chengzhi Zhao, Xueer Zhou, Zhiwei Cao, et al.
Phytomedicine (2023) Vol. 119, pp. 154986-154986
Closed Access | Times Cited: 19
Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma
Shaokun Liu, Ru Wang, Jugao Fang
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Current Insights and Progress in the Clinical Management of Head and Neck Cancer
Mariana Amaral, Pedro Faísca, Hugo Alexandre Ferreira, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6079-6079
Open Access | Times Cited: 25
Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches
Giacomo Miserocchi, Chiara Spadazzi, Sebastiano Calpona, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 6, pp. 854-854
Open Access | Times Cited: 23
Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry
Tomohiro Fujii, Yutaka Matsuda
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1053-1065
Closed Access | Times Cited: 14
m7G‐related genes—NCBP2 and EIF4E3 determine immune contexture in head and neck squamous cell carcinoma by regulating CCL4/CCL5 expression
Xuhui Xu, Yue Zhao, Yukang Ying, et al.
Molecular Carcinogenesis (2023) Vol. 62, Iss. 8, pp. 1091-1106
Closed Access | Times Cited: 13
Progress in the study of reproductive toxicity of platinum-based antitumor drugs and their means of prevention
Zhan Jin, Zhaoxia Liu, Peng Fan-Ke, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Disulfiram/Copper Activates ER Stress to Promote Immunogenic Cell Death of Oral Squamous Cell Carcinoma
Yanjuan Zhao, Bo Zhao, Shujin Zhu
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 2, pp. 1291-1298
Closed Access | Times Cited: 5
Guanylate binding protein 5 is an immune‐related biomarker of oral squamous cell carcinoma: A retrospective prognostic study with bioinformatic analysis
Masayo Hasegawa, Yusuke Amano, Atsushi Kihara, et al.
Cancer Medicine (2024) Vol. 13, Iss. 13
Open Access | Times Cited: 5
Current Challenges in Head and Neck Cancer Management
Anna Starzyńska, Bartosz Kamil Sobocki, Daniela Alterio
Cancers (2022) Vol. 14, Iss. 2, pp. 358-358
Open Access | Times Cited: 22
Mechanism of METTL14 and m6A modification of lncRNA MALAT1 in the proliferation of oral squamous cell carcinoma cells
Jinli Li, Fatemeh Momen‐Heravi, Xun Wu, et al.
Oral Diseases (2022) Vol. 29, Iss. 5, pp. 2012-2026
Closed Access | Times Cited: 21
MALAT1 as a potential salivary biomarker in oral squamous cell carcinoma through targeting miRNA‐124
Rania Shalaby, Sally Ibrahim, Ali A. W. Kotb, et al.
Oral Diseases (2023) Vol. 30, Iss. 4, pp. 2075-2083
Closed Access | Times Cited: 13
Nanoparticles as drug delivery systems in the treatment of oral squamous cell carcinoma: current status and recent progression
Shu-Xia Cui, Hanzhe Liu, Guanglin Cui
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis
Li Xie, Jinzhuang Liao, Wenbin Liu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 11
METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC
Lianlian Liu, Tingting Zhao, Siyi Zheng, et al.
Oral Diseases (2024) Vol. 30, Iss. 7, pp. 4243-4254
Closed Access | Times Cited: 4
RUVBL1 accelerates tongue squamous cell carcinoma by mediating CRaf/MEK/ERK pathway
Xinyu Zhang, Yang Liu, Qiong Rong, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109434-109434
Open Access | Times Cited: 4
Novel Predictive Biomarkers in the Head and Neck Squamous Cell Carcinoma (HNSCC)
Magdalena Miniuk, Joanna Reszeć-Giełażyn, Piotr Bortnik, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 19, pp. 5876-5876
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top